

# Walpole

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	27.4	76.7	(47.4-117.2)	Male	24	17.8	134.5	(86.1-200.1)
Female	12	10.0	120.4	(62.1-210.3)	Female	13	13.7	95.0	(50.5-162.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.3	113.5	(41.4-247.0)	Male	6	5.6	106.6	(38.9-232.0)
Female	5	4.3	115.1	(37.1-268.5)	Female	5	4.5	111.5	(35.9-260.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	12	15.9	75.3	(38.8-131.5)
Female	137	107.7	127.2	(106.8-150.3)	Female	11	13.8	79.5	(39.6-142.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.6	nc	(nc-nc)	Male	9	13.2	67.9	(31.0-129.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	35	30.1	116.3	(81.0-161.7)	Female	12	9.6	125.6	(64.8-219.3)
Female	32	30.4	105.2	(71.9-148.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	9.8	112.2	(55.9-200.8)
Male	5	7.4	67.1	(21.6-156.7)	Female	8	10.1	79.6	(34.3-156.8)
Female	2	1.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	117	96.0	121.8	(100.8-146.0)
Male	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	6	6.5	92.4	(33.7-201.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.9	nc	(nc-nc)
Male	17	15.5	109.9	(64.0-176.0)	<b><u>Testis</u></b>				
Female	6	8.6	69.8	(25.5-151.9)	Male	3	3.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	4.3	161.7	(64.8-333.2)	Male	6	7.1	85.0	(31.1-185.1)
Female	2	1.2	nc	(nc-nc)	Female	19	19.2	99.2	(59.7-154.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	11.0	63.9	(25.6-131.6)	Female	22	24.4	90.2	(56.5-136.6)
Female	11	8.1	135.8	(67.7-243.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	376	366.6	102.6	(92.5-113.5)
Male	7	9.8	71.2	(28.5-146.7)	Female	384	367.0	104.6	(94.4-115.6)
Female	3	3.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	40	49.2	81.2	(58.0-110.6)					
Female	47	51.5	91.2	(67.0-121.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Waltham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	61	52.5	116.2	(88.9-149.3)	Male	25	35.8	69.9	(45.2-103.2)
Female	21	20.2	104.0	(64.3-158.9)	Female	14	30.7	45.6	(24.9-76.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	11.4	132.0	(73.8-217.8)	Male	9	10.7	83.8	(38.3-159.1)
Female	13	9.5	136.8	(72.8-233.9)	Female	4	9.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	26	31.7	82.0	(53.5-120.1)
Female	234	221.2	105.8	(92.7-120.2)	Female	32	28.6	111.8	(76.4-157.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	8.2	109.7	(50.1-208.3)	Male	16	25.4	63.1	(36.0-102.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	60	57.2	104.8	(80.0-134.9)	Female	18	20.1	89.4	(52.9-141.3)
Female	56	60.8	92.1	(69.6-119.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	21	18.7	112.5	(69.6-171.9)
Male	13	14.1	92.1	(49.0-157.4)	Female	25	20.4	122.8	(79.4-181.2)
Female	3	3.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	146	181.6	80.4	(67.9-94.5)
Male	4	5.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	4.8	104.2	(33.6-243.1)	Male	18	12.5	144.2	(85.4-227.9)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	9	7.9	114.2	(52.1-216.9)
Male	36	30.1	119.6	(83.7-165.5)	<b><u>Testis</u></b>				
Female	16	17.8	89.9	(51.4-146.1)	Male	12	11.3	105.8	(54.6-184.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	8.3	60.1	(19.4-140.2)	Male	17	15.2	112.1	(65.3-179.5)
Female	2	2.6	nc	(nc-nc)	Female	53	46.6	113.7	(85.1-148.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	22.2	85.5	(51.4-133.5)	Female	41	50.5	81.2	(58.3-110.2)
Female	13	17.3	75.3	(40.1-128.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	667	715.5	93.2	(86.3-100.6)
Male	19	18.6	102.0	(61.4-159.3)	Female	750	765.7	98.0	(91.1-105.2)
Female	5	6.4	77.6	(25.0-181.2)					
<b><u>Lung and Bronchus</u></b>									
Male	93	95.6	97.3	(78.5-119.2)					
Female	109	105.4	103.4	(84.9-124.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ware

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	10.5	66.4	(26.6-136.8)	Male	4	7.0	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	7	6.3	111.6	(44.7-230.0)
Female	34	47.4	71.8	(49.7-100.3)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	11.8	127.5	(71.3-210.3)	Female	5	4.2	118.7	(38.2-277.0)
Female	16	12.2	131.1	(74.9-212.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	3.8	208.1	(89.6-410.0)
Male	2	3.0	nc	(nc-nc)	Female	6	4.0	149.9	(54.7-326.3)
Female	2	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	29	39.4	73.7	(49.3-105.8)
Male	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.6	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	8	3.7	216.5	(93.2-426.6)	Male	2	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	8.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	4.3	nc	(nc-nc)	Female	9	10.9	82.8	(37.8-157.2)
Female	3	3.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	134	145.8	91.9	(77.0-108.9)
Male	5	4.0	125.2	(40.3-292.1)	Female	134	156.2	85.8	(71.9-101.6)
Female	1	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	21	19.3	109.0	(67.4-166.6)					
Female	16	21.8	73.3	(41.8-119.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wareham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	29.7	128.0	(90.6-175.7)	Male	17	18.2	93.2	(54.3-149.3)
Female	15	10.1	148.3	(82.9-244.6)	Female	14	13.8	101.6	(55.5-170.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.0	158.4	(68.2-312.2)	Male	10	5.9	170.7	(81.7-314.0)
Female	3	4.2	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	17	16.2	104.9	(61.1-167.9)
Female	94	109.9	85.5	(69.1-104.6)	Female	8	13.9	57.4	(24.7-113.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.5	nc	(nc-nc)	Male	15	12.5	119.6	(66.9-197.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	33	30.8	107.2	(73.8-150.5)	Female	9	9.8	92.0	(42.0-174.7)
Female	39	30.3	128.7	(91.5-175.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	10.2	98.2	(47.0-180.6)
Male	7	7.5	93.1	(37.3-191.8)	Female	12	10.1	118.5	(61.2-207.1)
Female	2	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	87	92.4	94.1	(75.4-116.1)
Male	0	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.5	nc	(nc-nc)	Male	6	6.8	88.3	(32.3-192.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.9	nc	(nc-nc)
Male	16	14.9	107.3	(61.3-174.2)	<b><u>Testis</u></b>				
Female	15	8.8	171.2	(95.7-282.3)	Male	4	3.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	4.4	114.1	(36.8-266.2)	Male	7	6.3	110.5	(44.3-227.8)
Female	4	1.3	nc	(nc-nc)	Female	18	18.9	95.0	(56.3-150.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	11.2	80.3	(36.7-152.5)	Female	20	25.3	79.2	(48.3-122.3)
Female	18	8.0	226.0	(133.9-357.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	412	370.2	111.3	(100.8-122.6)
Male	14	9.7	144.5	(78.9-242.5)	Female	401	372.6	107.6	(97.4-118.7)
Female	5	3.2	155.9	(50.2-363.7)					
<b><u>Lung and Bronchus</u></b>									
Male	79	52.7	150.0	(118.7-186.9)					
Female	82	53.7	152.6	(121.4-189.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warren

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.2	116.5	(42.5-253.6)	Male	2	3.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	15	22.0	68.1	(38.1-112.3)	Female	1	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	5.7	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	7	5.7	123.5	(49.5-254.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	1.8	380.8	(152.6-784.7)
Male	2	1.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	15	18.7	80.3	(44.9-132.4)
Male	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.7	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.1	nc	(nc-nc)	Female	6	5.0	120.1	(43.8-261.3)
Female	2	1.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	61	69.8	87.4	(66.8-112.2)
Male	2	1.8	nc	(nc-nc)	Female	51	72.4	70.5	(52.5-92.7)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	9	9.3	96.4	(44.0-183.0)					
Female	8	9.9	81.1	(34.9-159.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	6	4.1	148.0	(54.1-322.2)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	14	14.6	95.7	(52.3-160.6)
Male	0	0.4	nc	(nc-nc)	Female	14	14.2	98.3	(53.7-164.9)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	3	2.1	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Male</u></b>					<b><u>Female</u></b>				
					4				
					8				
					11.8				
					9.0				
					88.7				
					(38.2-174.7)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	33.3	105.2	(73.2-146.3)	Male	14	21.7	64.6	(35.3-108.5)
Female	9	13.1	68.7	(31.4-130.4)	Female	21	19.0	110.8	(68.5-169.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.5	153.1	(73.3-281.7)	Male	5	6.7	74.3	(23.9-173.4)
Female	9	5.6	161.1	(73.5-305.7)	Female	5	5.9	85.2	(27.4-198.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	20	19.3	103.7	(63.3-160.1)
Female	149	141.2	105.5	(89.2-123.9)	Female	21	18.4	114.4	(70.8-174.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.1	155.8	(67.1-307.0)	Male	15	14.8	101.5	(56.8-167.4)
Female					Female	3	7.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	45	36.2	124.3	(90.6-166.3)	Female	15	12.7	118.3	(66.2-195.1)
Female	38	39.0	97.5	(69.0-133.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	11.4	105.4	(54.4-184.1)
Male	9	8.4	106.9	(48.8-202.9)	Female	18	13.1	137.1	(81.2-216.8)
Female	1	2.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	92	102.0	90.2	(72.7-110.7)
Male	4	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	8	7.8	102.4	(44.1-201.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	11	5.0	<b>220.3</b>	<b>(109.8-394.3)</b>
Male	23	17.9	128.2	(81.2-192.3)	<b><u>Testis</u></b>				
Female	4	11.4	nc	(nc-nc)	Male	5	5.8	86.4	(27.9-201.7)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	5.0	100.8	(32.5-235.2)	Male	12	8.6	139.2	(71.9-243.2)
Female	1	1.7	nc	(nc-nc)	Female	24	28.1	85.5	(54.8-127.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	13.4	89.3	(46.1-156.0)	Female	26	31.9	81.5	(53.2-119.4)
Female	10	10.4	95.8	(45.8-176.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	417	427.2	97.6	(88.5-107.4)
Male	10	11.0	90.8	(43.5-167.1)	Female	470	487.1	96.5	(88.0-105.6)
Female	6	4.1	146.0	(53.3-317.7)					
<b><u>Lung and Bronchus</u></b>									
Male	52	58.7	88.7	(66.2-116.3)					
Female	61	70.1	87.1	(66.6-111.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	17.7	45.1	(19.4-88.9)	Male	15	10.9	137.6	(76.9-226.9)
Female	5	6.2	80.2	(25.8-187.2)	Female	16	8.3	192.8	(110.1-313.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	5	3.5	141.1	(45.5-329.2)
Female	4	2.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.8	102.3	(49.0-188.1)
Female	83	69.3	119.7	(95.3-148.4)	Female	11	8.6	127.2	(63.4-227.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	2	7.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	18.7	64.1	(33.1-112.0)	Female	4	6.1	nc	(nc-nc)
Female	9	18.5	48.6	(22.2-92.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	6.2	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	Female	5	6.3	80.0	(25.8-186.6)
Female	0	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	67	56.6	118.3	(91.7-150.3)
Male	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	2.4	nc	(nc-nc)
Male	8	9.2	87.3	(37.6-172.0)	<b><u>Testis</u></b>				
Female	4	5.5	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	7	3.9	181.6	(72.8-374.3)
Female	0	0.8	nc	(nc-nc)	Female	11	11.1	99.3	(49.5-177.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	6.7	118.5	(51.0-233.6)	Female	12	16.1	74.4	(38.4-130.0)
Female	2	4.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	197	223.5	88.2	(76.3-101.4)
Male	3	5.9	nc	(nc-nc)	Female	205	231.5	88.6	(76.8-101.5)
Female	1	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	31.3	63.9	(39.0-98.6)					
Female	21	33.9	61.9	(38.3-94.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Webster

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	19.7	157.6	(107.1-223.7)	Male	10	12.3	81.5	(39.0-149.9)
Female	7	7.6	92.4	(37.0-190.4)	Female	6	10.1	59.4	(21.7-129.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	Female	7	3.3	210.8	(84.5-434.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	0.7	nc	(nc-nc)	Male	12	11.0	109.2	(56.3-190.7)
Female	78	76.6	101.8	(80.5-127.1)	Female	9	10.2	87.9	(40.1-166.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	4	8.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	28	21.0	133.3	(88.6-192.7)	Female	9	6.9	130.4	(59.5-247.5)
Female	27	23.0	117.2	(77.2-170.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	7	5.0	139.1	(55.7-286.6)	Male	56	62.5	89.6	(67.7-116.4)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Thyroid</u></b>				
Male	10	10.2	97.6	(46.7-179.6)	Male	6	4.6	131.7	(48.1-286.7)
Female	7	6.2	113.1	(45.3-233.0)	Female	12	14.0	85.7	(44.2-149.8)
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	2.9	172.4	(55.5-402.2)	Female	18	16.8	107.1	(63.4-169.2)
Female	2	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	7.6	144.8	(72.2-259.0)	Male	282	249.6	113.0	(100.2-127.0)
Female	7	6.1	115.6	(46.3-238.2)	Female	284	268.1	105.9	(94.0-119.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	10	6.5	154.5	(74.0-284.1)					
Female	6	2.3	264.1	(96.4-574.9)					
<b><u>Lung and Bronchus</u></b>									
Male	42	34.6	121.3	(87.4-164.0)					
Female	48	37.9	126.5	(93.3-167.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellesley

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	29.7	70.8	(43.8-108.2)	Male	30	18.5	162.2	(109.4-231.6)
Female	5	9.9	50.5	(16.3-118.0)	Female	31	14.0	221.7	(150.6-314.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.5	nc	(nc-nc)	Male	5	5.9	84.9	(27.4-198.2)
Female	4	4.8	nc	(nc-nc)	Female	7	4.4	159.3	(63.8-328.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	16	16.7	96.1	(54.9-156.1)
Female	134	108.5	123.5	(103.5-146.3)	Female	12	13.8	86.8	(44.8-151.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.6	nc	(nc-nc)	Male	8	13.3	60.2	(25.9-118.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	31.5	63.4	(38.7-98.0)	Female	10	9.7	102.9	(49.3-189.3)
Female	25	29.8	83.8	(54.2-123.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	10.4	96.5	(46.2-177.6)
Male	2	7.8	nc	(nc-nc)	Female	11	9.9	111.5	(55.6-199.5)
Female	2	1.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	122	97.8	124.7	(103.6-148.9)
Male	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.9	nc	(nc-nc)
Male	8	15.8	50.8	(21.9-100.1)	<b><u>Testis</u></b>				
Female	8	8.6	92.8	(40.0-182.9)	Male	2	3.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	10	6.8	147.7	(70.7-271.6)
Female	1	1.3	nc	(nc-nc)	Female	17	20.6	82.4	(48.0-132.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	11.8	101.4	(52.3-177.1)	Female	17	24.1	70.6	(41.1-113.1)
Female	12	8.4	142.7	(73.6-249.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	327	381.3	85.8	(76.7-95.6)
Male	6	9.9	60.7	(22.2-132.2)	Female	367	370.5	99.1	(89.2-109.7)
Female	1	3.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	17	52.5	32.4	(18.8-51.8)					
Female	33	52.0	63.4	(43.6-89.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.2	97.8	(39.2-201.4)	Male	4	4.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	5	3.0	164.3	(52.9-383.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	22	25.2	87.4	(54.7-132.3)	Female	2	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	6.7	165.4	(82.4-295.9)	Female	2	2.3	nc	(nc-nc)
Female	6	7.7	78.4	(28.6-170.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	5	2.8	177.5	(57.2-414.3)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	21	24.7	85.1	(52.7-130.1)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.0	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	2.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.4	nc	(nc-nc)	Female	3	6.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	71	88.2	80.5	(62.9-101.6)
Male	1	2.2	nc	(nc-nc)	Female	71	90.4	78.6	(61.3-99.1)
Female	1	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	13.5	36.9	(11.9-86.2)					
Female	12	14.7	81.4	(42.0-142.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wendell

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	5.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
					Male	11	21.0	52.4	(26.1-93.9)
					Female	10	15.9	63.0	(30.2-115.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wenham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.1	156.4	(67.3-308.1)	Male	6	3.1	191.3	(69.8-416.3)
Female	0	1.6	nc	(nc-nc)	Female	6	2.3	264.3	(96.5-575.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	22	17.3	127.1	(79.6-192.5)	Female	2	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	5.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	7	4.8	145.1	(58.2-299.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	24	14.8	162.1	(103.8-241.2)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.8	nc	(nc-nc)	Female	8	3.9	207.3	(89.3-408.6)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	67	62.8	106.6	(82.6-135.4)
Female	0	1.3	nc	(nc-nc)	Female	73	59.0	123.6	(96.9-155.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	1.6	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	4	9.0	nc	(nc-nc)					
Female	10	8.1	123.7	(59.2-227.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	9.0	210.3	(126.6-328.4)	Male	5	6.1	82.3	(26.5-192.1)
Female	3	3.2	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.4	92.6	(29.8-216.0)
Female	31	30.3	102.3	(69.5-145.1)	Female	4	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	9.8	nc	(nc-nc)	Female	5	2.8	181.0	(58.3-422.4)
Female	6	9.4	63.9	(23.3-139.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	3.2	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	20	30.9	64.7	(39.5-100.0)
Male	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.2	nc	(nc-nc)
Male	7	5.1	137.1	(54.9-282.6)	<b><u>Testis</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	11	4.8	229.1	(114.2-409.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.8	nc	(nc-nc)	Female	5	7.0	71.6	(23.1-167.1)
Female	1	2.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	114	121.7	93.7	(77.3-112.5)
Male	1	3.2	nc	(nc-nc)	Female	109	107.8	101.1	(83.0-121.9)
Female	2	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	16.1	123.9	(75.6-191.3)					
Female	12	16.2	74.3	(38.3-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.9	78.9	(31.6-162.6)	Male	10	5.5	183.4	(87.8-337.3)
Female	3	2.9	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.6	317.9	(102.4-741.8)	Male	0	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.9	102.5	(33.0-239.2)
Female	34	31.5	108.1	(74.8-151.0)	Female	8	4.0	200.4	(86.3-394.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	5	3.8	131.6	(42.4-307.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	9.2	75.8	(30.4-156.1)	Female	1	2.8	nc	(nc-nc)
Female	16	8.6	186.7	(106.7-303.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	3.1	nc	(nc-nc)
Male	6	2.3	263.3	(96.2-573.2)	Female	3	2.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	27	28.4	95.0	(62.6-138.2)
Male	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.1	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	11	5.6	196.9	(98.2-352.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	3.4	nc	(nc-nc)	Female	3	7.2	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	111	111.8	99.3	(81.7-119.6)
Male	2	2.9	nc	(nc-nc)	Female	121	106.5	113.6	(94.2-135.7)
Female	0	0.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	15	15.6	96.4	(53.9-159.0)					
Female	18	15.1	119.5	(70.8-188.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	13	16.7	77.7	(41.4-132.9)	Female	2	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	5.6	108.1	(39.5-235.3)	Female	4	1.6	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	1.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	11	16.9	65.0	(32.4-116.3)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.7	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.0	nc	(nc-nc)	Female	6	3.9	154.5	(56.4-336.3)
Female	1	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	50	67.3	74.3	(55.2-98.0)
Male	3	1.8	nc	(nc-nc)	Female	61	59.4	102.6	(78.5-131.8)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	9	9.5	94.5	(43.1-179.3)					
Female	15	8.5	177.3	(99.2-292.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Newbury

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	22	17.4	126.5	(79.3-191.6)	Female	0	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	5.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	17	18.0	94.4	(55.0-151.2)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	2.8	180.8	(58.3-422.0)	Female	4	4.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	2	8.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	7.2	69.6	(22.4-162.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	30.4	111.8	(77.4-156.3)	Male	14	19.6	71.5	(39.0-119.9)
Female	6	11.7	51.5	(18.8-112.0)	Female	12	16.0	75.2	(38.8-131.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.0	116.7	(46.7-240.4)	Male	3	6.1	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	17.5	85.9	(48.1-141.7)
Female	102	122.7	83.1	(67.8-100.9)	Female	8	15.9	50.3	(21.7-99.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	4.1	242.2	(116.0-445.5)	Male	18	14.1	127.7	(75.6-201.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	41	32.4	126.5	(90.8-171.7)	Female	9	11.0	81.8	(37.3-155.3)
Female	41	35.0	117.3	(84.1-159.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	10.7	112.2	(57.9-196.0)
Male	11	8.1	135.5	(67.5-242.5)	Female	9	11.6	77.4	(35.3-146.9)
Female	1	2.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	82	103.8	79.0	(62.9-98.1)
Male	3	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.5	nc	(nc-nc)
Male	14	16.6	84.2	(46.0-141.2)	<b><u>Testis</u></b>				
Female	9	10.0	90.4	(41.3-171.7)	Male	5	4.4	113.4	(36.6-264.7)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	9	7.6	118.9	(54.2-225.7)
Female	2	1.5	nc	(nc-nc)	Female	21	22.6	93.1	(57.6-142.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	12.3	64.9	(28.0-128.0)	Female	27	27.6	98.0	(64.6-142.6)
Female	10	9.4	106.8	(51.1-196.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	371	401.6	92.4	(83.2-102.3)
Male	13	10.6	122.5	(65.1-209.4)	Female	411	423.2	97.1	(88.0-107.0)
Female	3	3.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	48	54.8	87.7	(64.6-116.2)					
Female	85	60.6	140.3	(112.1-173.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	7.7	91.3	(36.6-188.0)	Female	3	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	11	7.1	155.4	(77.5-278.1)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	30	25.6	117.2	(79.1-167.3)
Male	1	0.7	nc	(nc-nc)	Female	24	25.9	92.7	(59.4-138.0)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	3.6	169.0	(61.7-367.9)					
Female	3	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.4	254.5	(92.9-554.0)	Male	3	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	20	14.5	137.7	(84.0-212.6)	Female	2	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	2.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.9	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	11	10.7	103.1	(51.4-184.5)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.5	nc	(nc-nc)
Male	6	1.5	403.5	(147.4-878.4)	<b><u>Testis</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.0	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	48	34.9	137.7	(101.5-182.5)
Male	0	0.9	nc	(nc-nc)	Female	51	48.2	105.8	(78.8-139.1)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	4.6	nc	(nc-nc)					
Female	7	6.5	107.2	(42.9-220.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.4	68.9	(35.6-120.4)	Male	13	11.7	111.3	(59.2-190.3)
Female	7	6.6	105.3	(42.2-217.0)	Female	5	9.6	52.0	(16.8-121.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.6	137.6	(44.4-321.2)	Male	7	3.6	192.2	(77.0-396.1)
Female	3	3.1	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	10.5	95.3	(45.6-175.2)
Female	84	73.8	113.8	(90.8-140.9)	Female	7	9.3	75.3	(30.2-155.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	7	8.5	82.3	(33.0-169.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	19.8	85.8	(50.0-137.4)	Female	5	6.6	75.9	(24.5-177.1)
Female	25	20.8	120.2	(77.7-177.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	6.1	81.3	(26.2-189.8)
Male	4	4.6	nc	(nc-nc)	Female	6	6.8	88.0	(32.1-191.6)
Female	2	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	54	56.6	95.4	(71.7-124.5)
Male	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.7	nc	(nc-nc)
Male	8	10.0	79.9	(34.4-157.5)	<b><u>Testis</u></b>				
Female	2	5.7	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	8	4.9	163.6	(70.4-322.3)
Female	0	0.8	nc	(nc-nc)	Female	12	14.2	84.3	(43.5-147.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	7.3	123.9	(56.6-235.3)	Female	19	16.2	117.4	(70.7-183.4)
Female	9	5.6	159.7	(72.9-303.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	215	232.1	92.6	(80.7-105.9)
Male	5	6.2	80.5	(25.9-187.8)	Female	241	249.4	96.6	(84.8-109.6)
Female	0	2.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	30.8	74.6	(47.3-112.0)					
Female	33	32.7	100.9	(69.5-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	44	41.8	105.2	(76.5-141.3)	Male	24	26.9	89.1	(57.1-132.6)
Female	14	15.0	93.1	(50.8-156.2)	Female	20	21.4	93.3	(57.0-144.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	8.3	60.5	(19.5-141.3)	Male	9	8.4	107.1	(48.9-203.3)
Female	7	6.8	102.6	(41.1-211.4)	Female	0	6.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	21	24.2	86.7	(53.6-132.5)
Female	183	165.1	110.8	(95.3-128.1)	Female	19	21.0	90.3	(54.4-141.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.5	146.1	(62.9-287.9)	Male	13	19.4	66.9	(35.6-114.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	47	45.3	103.9	(76.3-138.1)	Female	19	14.8	128.1	(77.1-200.1)
Female	52	45.3	114.7	(85.7-150.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	14.7	61.1	(27.9-115.9)
Male	15	11.1	135.6	(75.9-223.7)	Female	13	15.2	85.8	(45.6-146.7)
Female	3	2.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	124	140.7	88.2	(73.3-105.1)
Male	6	3.5	173.7	(63.4-378.0)	<b><u>Stomach</u></b>				
Female	1	3.0	nc	(nc-nc)	Male	15	9.8	152.9	(85.5-252.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	5.9	102.4	(37.4-223.0)
Male	17	22.8	74.5	(43.4-119.2)	<b><u>Testis</u></b>				
Female	10	13.1	76.1	(36.4-139.9)	Male	5	6.3	80.0	(25.8-186.6)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	6.4	nc	(nc-nc)	Male	6	10.5	56.9	(20.8-124.0)
Female	3	2.0	nc	(nc-nc)	Female	19	30.7	61.8	(37.2-96.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	22	17.1	128.9	(80.8-195.2)	Female	33	38.0	86.9	(59.8-122.1)
Female	11	12.5	88.3	(44.0-158.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	529	550.9	96.0	(88.0-104.6)
Male	12	14.5	82.6	(42.6-144.3)	Female	547	562.9	97.2	(89.2-105.7)
Female	2	4.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	79	74.3	106.3	(84.2-132.5)					
Female	81	78.8	102.8	(81.6-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	19.3	62.3	(32.1-108.8)	Male	19	13.8	137.6	(82.8-214.9)
Female	4	6.4	nc	(nc-nc)	Female	12	10.9	109.9	(56.7-191.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	7	4.4	160.7	(64.4-331.2)
Female	6	3.5	171.2	(62.5-372.6)	Female	3	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	13	12.4	104.5	(55.6-178.7)
Female	88	89.9	97.9	(78.5-120.6)	Female	8	9.9	80.7	(34.8-159.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.2	nc	(nc-nc)	Male	10	11.4	87.8	(42.0-161.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	22.9	91.5	(56.6-139.9)	Female	6	7.7	78.1	(28.5-170.0)
Female	21	20.2	104.1	(64.4-159.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	76	81.8	92.9	(73.2-116.3)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	13.1	84.2	(42.0-150.7)	Female	35	20.8	168.4	(117.3-234.2)
Female	3	6.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	6	3.6	166.9	(61.0-363.4)	Male	13	8.4	154.9	(82.4-264.9)
Female	0	1.0	nc	(nc-nc)	Female	11	5.7	193.1	(96.3-345.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	5	8.2	61.3	(19.8-143.1)	Male	36	37.1	97.0	(68.0-134.3)
Female	0	2.3	nc	(nc-nc)	Female	28	35.9	78.0	(51.8-112.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	6	1.2	503.9	(184.0-1096.8)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	11	7.6	145.5	(72.5-260.4)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.1	nc	(nc-nc)	Female	8	7.0	114.3	(49.2-225.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	2	3.3	nc	(nc-nc)	Female	25	25.1	99.6	(64.4-147.0)
Female	0	3.1	nc	(nc-nc)	Female	17	23.9	71.2	(41.4-114.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westminster

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.5	93.7	(37.5-193.1)	Male	6	5.1	118.0	(43.1-256.9)
Female	1	2.1	nc	(nc-nc)	Female	6	3.6	166.9	(61.0-363.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	130.3	(47.6-283.7)
Female	43	29.2	147.3	(106.6-198.4)	Female	2	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	8.7	91.9	(39.6-181.1)	Female	4	2.5	nc	(nc-nc)
Female	7	6.5	106.9	(42.8-220.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	2.7	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	26	26.8	97.1	(63.4-142.3)
Male	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.8	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	7	5.9	118.9	(47.6-244.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.1	nc	(nc-nc)	Female	8	6.9	116.3	(50.1-229.2)
Female	1	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	100	103.5	96.6	(78.6-117.5)
Male	1	2.9	nc	(nc-nc)	Female	111	90.9	122.1	(100.4-147.0)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	9	13.2	68.0	(31.0-129.1)					
Female	14	11.2	125.4	(68.5-210.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weston

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	15.3	98.2	(54.9-161.9)	Male	11	9.3	118.1	(58.9-211.3)
Female	2	4.8	nc	(nc-nc)	Female	10	6.5	154.4	(73.9-284.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.3	108.4	(49.5-205.8)
Female	50	52.1	95.9	(71.2-126.4)	Female	4	6.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	6	6.6	91.4	(33.4-198.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	15.9	75.5	(39.0-132.0)	Female	2	4.7	nc	(nc-nc)
Female	13	14.4	90.4	(48.1-154.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.3	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	Female	8	4.8	166.8	(71.8-328.8)
Female	0	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	55	48.9	112.5	(84.7-146.4)
Male	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.9	nc	(nc-nc)
Male	4	7.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	4.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	6	3.2	189.1	(69.1-411.6)
Female	0	0.6	nc	(nc-nc)	Female	6	8.9	67.7	(24.7-147.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	5.9	153.2	(69.9-290.9)	Female	7	12.0	58.2	(23.3-119.9)
Female	10	3.9	258.2	(123.6-474.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	195	191.8	101.7	(87.9-117.0)
Male	4	5.0	nc	(nc-nc)	Female	153	176.6	86.6	(73.5-101.5)
Female	1	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	27.2	80.9	(50.7-122.5)					
Female	20	25.0	79.9	(48.8-123.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westport

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	23.4	128.2	(86.4-183.0)	Male	16	14.2	112.4	(64.2-182.5)
Female	10	7.5	132.9	(63.6-244.4)	Female	9	9.9	90.5	(41.3-171.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	5	4.6	108.6	(35.0-253.3)
Female	2	3.1	nc	(nc-nc)	Female	6	3.4	175.6	(64.1-382.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	15	12.6	119.2	(66.6-196.6)
Female	74	80.9	91.5	(71.8-114.8)	Female	16	10.4	154.3	(88.1-250.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	7	9.9	70.8	(28.4-145.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	23.7	84.3	(51.5-130.3)	Female	4	7.2	nc	(nc-nc)
Female	17	22.0	77.2	(45.0-123.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	9	6.1	148.1	(67.6-281.2)	Male	91	77.8	116.9	(94.2-143.6)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	11.9	84.0	(40.2-154.5)	Female	11	19.2	57.2	(28.5-102.4)
Female	5	6.5	77.1	(24.8-179.8)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	8	8.7	92.0	(39.6-181.3)
Female	0	1.0	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	5	7.6	65.8	(21.2-153.6)	Male	34	41.9	81.2	(56.2-113.5)
Female	1	2.4	nc	(nc-nc)	Female	38	40.4	94.2	(66.6-129.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westwood

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	20.0	99.8	(60.9-154.1)	Male	24	12.0	200.6	(128.5-298.4)
Female	5	7.5	66.7	(21.5-155.6)	Female	22	9.1	242.8	(152.1-367.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	5	3.8	131.0	(42.2-305.8)
Female	4	2.9	nc	(nc-nc)	Female	5	3.2	154.5	(49.8-360.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	9	10.8	83.0	(37.9-157.6)
Female	95	71.4	133.0	(107.6-162.6)	Female	4	9.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	7	8.3	84.6	(33.9-174.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	28	21.3	131.7	(87.5-190.4)	Female	9	6.5	139.2	(63.5-264.2)
Female	27	22.9	117.7	(77.6-171.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	6.9	160.5	(80.0-287.3)
Male	2	4.9	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	64	58.4	109.5	(84.4-139.9)
Male	4	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.0	nc	(nc-nc)
Male	10	9.7	102.7	(49.2-188.9)	<b><u>Testis</u></b>				
Female	6	5.8	103.5	(37.8-225.2)	Male	3	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	5	4.1	121.8	(39.3-284.2)
Female	0	0.8	nc	(nc-nc)	Female	19	11.3	167.7	(100.9-261.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	7.7	117.3	(53.5-222.7)	Female	19	15.6	121.5	(73.1-189.8)
Female	10	5.8	171.9	(82.3-316.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	260	242.7	107.1	(94.5-121.0)
Male	4	6.3	nc	(nc-nc)	Female	296	252.9	117.0	(104.1-131.1)
Female	4	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	25	33.7	74.2	(48.0-109.5)					
Female	37	36.2	102.1	(71.9-140.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	53	57.7	91.8	(68.7-120.1)	Male	40	37.5	106.7	(76.2-145.3)
Female	39	24.3	160.6	(114.2-219.6)	Female	45	33.5	134.5	(98.1-180.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	11.2	89.1	(42.6-163.8)	Male	16	11.8	135.7	(77.5-220.4)
Female	10	10.3	96.9	(46.4-178.3)	Female	7	11.0	63.9	(25.6-131.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	45	33.4	134.6	(98.2-180.1)
Female	275	264.7	103.9	(92.0-116.9)	Female	27	33.8	79.9	(52.6-116.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	8.8	56.8	(18.3-132.6)	Male	33	27.1	121.7	(83.7-170.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	66	62.9	104.9	(81.1-133.4)	Female	26	23.5	110.4	(72.1-161.8)
Female	77	73.2	105.2	(83.1-131.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	22	20.3	108.2	(67.8-163.8)
Male	14	15.4	91.1	(49.8-152.9)	Female	21	24.3	86.5	(53.5-132.2)
Female	4	4.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	179	194.0	92.3	(79.3-106.8)
Male	6	4.4	137.6	(50.2-299.5)	<b><u>Stomach</u></b>				
Female	1	3.8	nc	(nc-nc)	Male	13	13.6	95.4	(50.8-163.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	9.4	53.4	(17.2-124.7)
Male	35	31.9	109.7	(76.4-152.6)	<b><u>Testis</u></b>				
Female	27	21.0	128.4	(84.6-186.8)	Male	8	7.9	100.6	(43.3-198.3)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	17	9.0	189.4	(110.3-303.2)	Male	15	14.6	102.5	(57.3-169.0)
Female	3	3.2	nc	(nc-nc)	Female	54	47.1	114.7	(86.1-149.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	23.2	81.8	(49.2-127.7)	Female	64	60.5	105.8	(81.4-135.0)
Female	13	19.3	67.4	(35.9-115.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	796	761.6	104.5	(97.4-112.0)
Male	19	20.4	93.3	(56.2-145.7)	Female	955	898.6	106.3	(99.6-113.2)
Female	9	7.7	116.4	(53.1-221.0)					
<b><u>Lung and Bronchus</u></b>									
Male	112	103.5	108.2	(89.1-130.3)					
Female	155	128.0	121.1	(102.8-141.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whately

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	6.8	73.7	(23.8-172.0)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	6	7.2	83.1	(30.4-180.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	1.1	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whitman

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	14.4	208.6	(140.7-297.9)	Male	7	9.6	73.1	(29.3-150.6)
Female	5	4.6	107.9	(34.8-251.8)	Female	12	7.3	163.9	(84.6-286.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.6	nc	(nc-nc)
Female	54	57.3	94.3	(70.8-123.1)	Female	5	6.9	73.0	(23.5-170.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.1	243.4	(78.5-568.1)	Male	5	7.1	70.0	(22.6-163.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	16.0	99.8	(57.0-162.1)	Female	2	5.0	nc	(nc-nc)
Female	20	14.4	139.3	(85.1-215.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	5.2	nc	(nc-nc)
Male	6	4.0	151.6	(55.3-329.9)	Female	5	4.6	107.8	(34.7-251.5)
Female	1	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	51	51.4	99.2	(73.9-130.5)
Male	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.8	nc	(nc-nc)
Male	19	8.4	225.7	(135.8-352.5)	<b><u>Testis</u></b>				
Female	3	4.4	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	2.3	217.1	(70.0-506.7)	Male	2	4.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	10	11.4	87.9	(42.1-161.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	6.0	132.8	(57.2-261.7)	Female	12	13.2	91.2	(47.1-159.4)
Female	3	4.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	213	196.5	108.4	(94.3-124.0)
Male	4	5.2	nc	(nc-nc)	Female	196	187.9	104.3	(90.2-120.0)
Female	0	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	35	26.0	134.8	(93.9-187.5)					
Female	37	25.2	147.0	(103.5-202.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	21.6	69.3	(38.8-114.3)	Male	22	13.0	168.8	(105.7-255.6)
Female	9	7.3	123.5	(56.4-234.5)	Female	9	9.3	97.2	(44.3-184.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	7	2.8	246.2	(98.6-507.2)	Female	2	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	8	11.6	69.0	(29.7-136.0)
Female	83	74.9	110.8	(88.2-137.3)	Female	11	9.7	113.4	(56.5-202.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.2	nc	(nc-nc)	Male	6	9.1	66.2	(24.2-144.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	22.2	80.9	(47.9-127.9)	Female	4	6.8	nc	(nc-nc)
Female	15	21.9	68.5	(38.3-113.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	7.5	nc	(nc-nc)
Male	3	5.5	nc	(nc-nc)	Female	13	7.4	175.5	(93.4-300.1)
Female	3	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	50	68.7	72.8	(54.0-95.9)
Male	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.9	101.5	(32.7-236.9)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.9	nc	(nc-nc)
Male	10	10.7	93.2	(44.6-171.4)	<b><u>Testis</u></b>				
Female	4	6.0	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	5	4.3	115.1	(37.1-268.6)
Female	1	0.9	nc	(nc-nc)	Female	10	11.8	84.4	(40.4-155.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	8.1	nc	(nc-nc)	Female	12	17.2	70.0	(36.1-122.2)
Female	8	5.6	142.7	(61.4-281.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	211	268.4	78.6	(68.4-90.0)
Male	8	7.0	114.9	(49.5-226.4)	Female	240	257.1	93.3	(81.9-105.9)
Female	2	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	26	38.2	68.0	(44.4-99.7)					
Female	24	37.1	64.7	(41.5-96.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	18	14.0	128.5	(76.1-203.1)	Female	1	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	3.6	nc	(nc-nc)	Female	5	1.3	398.3	(128.4-929.5)
Female	5	3.8	133.2	(42.9-310.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.5	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	32	45.7	70.0	(47.9-98.8)
Female	1	1.0	nc	(nc-nc)	Female	45	46.5	96.7	(70.5-129.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	1.3	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	3	6.1	nc	(nc-nc)					
Female	2	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.9	67.3	(29.0-132.7)	Male	4	6.6	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.0	100.7	(36.8-219.2)
Female	26	35.0	74.3	(48.5-108.8)	Female	5	5.2	96.2	(31.0-224.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	11.6	60.5	(24.2-124.7)	Female	4	3.3	nc	(nc-nc)
Female	8	12.0	66.7	(28.7-131.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	36	33.1	108.9	(76.3-150.8)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.1	nc	(nc-nc)	Female	3	8.0	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	99	136.0	72.8	(59.2-88.6)
Female	0	0.5	nc	(nc-nc)	Female	93	131.1	71.0	(57.3-86.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	2	3.1	nc	(nc-nc)	Male	99	136.0	72.8	(59.2-88.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	3.3	nc	(nc-nc)	Female	93	131.1	71.0	(57.3-86.9)
Female	3	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	19.9	45.3	(20.7-86.0)	Male	99	136.0	72.8	(59.2-88.6)
Female	15	19.9	75.4	(42.2-124.3)	Female	93	131.1	71.0	(57.3-86.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	21.8	123.9	(81.7-180.3)	Male	11	14.4	76.3	(38.1-136.6)
Female	8	8.1	98.4	(42.4-193.9)	Female	15	12.1	124.3	(69.5-205.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	8	3.7	215.3	(92.7-424.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	8	13.1	61.3	(26.4-120.7)
Female	110	96.5	114.0	(93.7-137.4)	Female	16	11.6	138.1	(78.9-224.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	9	10.8	83.5	(38.1-158.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	24.5	98.0	(62.8-145.9)	Female	8	8.4	95.0	(40.9-187.1)
Female	27	24.8	108.7	(71.6-158.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	7.8	77.0	(28.1-167.7)
Male	5	5.9	84.9	(27.4-198.2)	Female	9	8.1	111.3	(50.8-211.3)
Female	0	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	62	74.4	83.3	(63.9-106.8)
Male	3	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.4	nc	(nc-nc)	Male	5	5.2	95.7	(30.8-223.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	3.2	157.4	(50.7-367.3)
Male	18	12.6	142.5	(84.4-225.2)	<b><u>Testis</u></b>				
Female	8	7.5	106.8	(46.0-210.4)	Male	0	3.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	8	5.9	135.0	(58.1-266.0)
Female	0	1.1	nc	(nc-nc)	Female	14	18.1	77.4	(42.3-129.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	13	9.2	141.1	(75.0-241.2)	Female	23	21.7	106.1	(67.2-159.2)
Female	5	6.8	73.5	(23.7-171.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	291	293.3	99.2	(88.1-111.3)
Male	4	7.8	nc	(nc-nc)	Female	347	317.8	109.2	(98.0-121.3)
Female	2	2.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	51	38.7	131.6	(98.0-173.1)					
Female	48	43.7	109.8	(80.9-145.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.6	103.4	(53.4-180.6)	Male	1	7.8	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	6.9	nc	(nc-nc)
Female	32	45.3	70.7	(48.3-99.8)	Female	3	5.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.5	nc	(nc-nc)	Male	6	5.9	101.3	(37.0-220.4)
<b><u>Colon / Rectum</u></b>					Female	2	2.3	nc	(nc-nc)
Male	8	13.0	61.5	(26.5-121.3)	<b><u>Ovary</u></b>				
Female	15	11.0	136.3	(76.2-224.8)	Female	6	3.9	153.2	(55.9-333.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	8	4.2	190.1	(81.9-374.6)
Female	2	0.7	nc	(nc-nc)	Female	5	3.5	142.5	(45.9-332.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	32	42.1	76.1	(52.0-107.4)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.8	nc	(nc-nc)
Male	5	6.8	73.6	(23.7-171.7)	Female	1	1.4	nc	(nc-nc)
Female	5	3.5	144.1	(46.4-336.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.5	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	8.3	95.9	(41.3-188.9)
Male	7	4.8	146.6	(58.7-302.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.9	nc	(nc-nc)	Female	10	10.3	97.3	(46.6-179.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	118	159.7	73.9	(61.1-88.5)
Female	0	1.2	nc	(nc-nc)	Female	139	145.8	95.3	(80.1-112.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	21.4	60.7	(32.3-103.9)					
Female	23	20.4	112.6	(71.3-168.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchester

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	23.6	101.5	(65.0-151.0)	Male	19	15.0	126.4	(76.1-197.4)
Female	5	9.2	54.1	(17.4-126.2)	Female	15	12.3	121.9	(68.2-201.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.4	nc	(nc-nc)	Male	5	4.8	104.2	(33.6-243.2)
Female	11	4.0	276.8	(138.0-495.4)	Female	6	4.1	146.8	(53.6-319.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	19	13.5	140.7	(84.7-219.8)
Female	115	98.8	116.4	(96.1-139.7)	Female	13	12.6	103.4	(55.0-176.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	4	10.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	25.7	93.3	(59.7-138.8)	Female	9	8.7	103.6	(47.3-196.6)
Female	27	28.2	95.6	(63.0-139.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	8.2	61.0	(19.7-142.4)
Male	3	6.1	nc	(nc-nc)	Female	8	9.3	85.6	(36.9-168.7)
Female	0	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	81	74.6	108.5	(86.2-134.9)
Male	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	3.7	136.5	(44.0-318.5)
Male	8	12.8	62.6	(27.0-123.4)	<b><u>Testis</u></b>				
Female	9	7.9	114.3	(52.2-217.1)	Male	2	2.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	22	17.2	127.6	(79.9-193.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	16	9.4	170.4	(97.3-276.8)	Female	24	21.5	111.8	(71.6-166.3)
Female	5	7.5	66.4	(21.4-154.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	285	302.8	94.1	(83.5-105.7)
Male	4	7.9	nc	(nc-nc)	Female	351	336.0	104.5	(93.8-116.0)
Female	2	2.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	29	41.9	69.2	(46.3-99.4)					
Female	41	47.5	86.4	(62.0-117.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Windsor

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	1.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	1	2.4	nc	(nc-nc)	Male	11	18.5	59.6	(29.7-106.6)
Female	3	1.9	nc	(nc-nc)	Female	16	14.3	111.8	(63.9-181.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	22.7	101.2	(64.1-151.8)	Male	28	14.7	190.2	(126.3-274.8)
Female	7	7.0	99.4	(39.8-204.9)	Female	18	10.2	176.3	(104.4-278.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	8	3.2	250.7	(107.9-494.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	4	12.9	nc	(nc-nc)
Female	88	79.2	111.0	(89.1-136.8)	Female	11	9.9	110.8	(55.2-198.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.7	nc	(nc-nc)	Male	10	10.7	93.0	(44.5-171.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	27	24.1	111.9	(73.7-162.8)	Female	12	7.0	170.7	(88.1-298.3)
Female	28	20.9	133.8	(88.9-193.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	14	8.1	173.0	(94.5-290.3)
Male	6	6.2	96.6	(35.3-210.2)	Female	7	7.0	100.5	(40.2-207.0)
Female	1	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	74	81.5	90.8	(71.3-114.0)
Male	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	5	5.4	93.4	(30.1-218.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.7	nc	(nc-nc)
Male	25	12.7	196.7	(127.2-290.3)	<b><u>Testis</u></b>				
Female	13	6.3	206.2	(109.7-352.6)	Male	2	2.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	9	5.6	161.3	(73.6-306.2)
Female	0	1.0	nc	(nc-nc)	Female	15	14.9	100.8	(56.4-166.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	8.9	67.7	(24.7-147.4)	Female	19	18.2	104.2	(62.7-162.8)
Female	6	5.7	105.7	(38.6-230.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	331	304.0	108.9	(97.5-121.3)
Male	8	8.1	98.7	(42.5-194.4)	Female	321	267.4	120.0	(107.3-133.9)
Female	3	2.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	55	42.0	130.9	(98.6-170.4)					
Female	49	38.3	127.8	(94.5-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Woburn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	40.7	120.3	(89.0-159.1)	Male	31	26.6	116.7	(79.2-165.6)
Female	23	15.8	145.2	(92.0-217.8)	Female	21	22.0	95.5	(59.1-145.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	8.0	nc	(nc-nc)	Male	9	8.2	109.5	(50.0-208.0)
Female	11	6.7	163.7	(81.6-292.9)	Female	7	7.1	99.0	(39.7-203.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	32	23.7	135.1	(92.4-190.7)
Female	208	167.5	124.2	(107.9-142.3)	Female	28	21.8	128.3	(85.3-185.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.7	156.7	(71.5-297.6)	Male	19	18.8	100.8	(60.7-157.4)
Female					Female	10	9.1	109.9	(52.6-202.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	60	44.4	135.1	(103.1-173.9)	Female	16	15.1	105.9	(60.5-172.0)
Female	51	48.1	106.1	(79.0-139.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	15	14.3	105.0	(58.7-173.2)
Male	12	10.6	112.8	(58.2-197.0)	Female	21	16.0	131.2	(81.2-200.5)
Female	1	3.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	125	133.4	93.7	(78.0-111.6)
Male	3	3.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	11	9.6	114.4	(57.1-204.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	6.2	96.7	(35.3-210.4)
Male	27	22.3	120.9	(79.7-175.9)	<b><u>Testis</u></b>				
Female	15	13.5	111.3	(62.3-183.7)	Male	9	6.5	137.8	(62.9-261.6)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	6.2	nc	(nc-nc)	Male	12	10.6	113.4	(58.5-198.0)
Female	5	2.0	250.3	(80.7-584.2)	Female	33	31.1	106.2	(73.1-149.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	16.5	121.5	(74.2-187.7)	Female	40	37.9	105.7	(75.5-143.9)
Female	15	12.8	117.0	(65.4-192.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	621	533.7	116.3	(107.4-125.9)
Male	17	14.0	121.5	(70.7-194.5)	Female	675	578.1	116.8	(108.1-125.9)
Female	1	4.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	98	72.1	136.0	(110.4-165.7)					
Female	81	81.4	99.5	(79.0-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worcester

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	181	152.2	118.9	(102.2-137.6)	Male	65	100.7	64.6	(49.8-82.3)
Female	62	61.8	100.4	(77.0-128.7)	Female	56	90.8	61.7	(46.6-80.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	30	32.7	91.6	(61.8-130.8)	Male	25	30.8	81.3	(52.6-120.0)
Female	24	28.9	82.9	(53.1-123.4)	Female	25	27.6	90.7	(58.7-133.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	5.2	nc	(nc-nc)	Male	103	91.1	113.1	(92.3-137.1)
Female	590	667.2	88.4	(81.4-95.9)	Female	80	86.5	92.4	(73.3-115.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	32	24.2	132.5	(90.6-187.0)	Male	67	72.3	92.7	(71.8-117.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	138	168.5	81.9	(68.8-96.8)	Female	60	60.8	98.8	(75.4-127.1)
Female	190	189.6	100.2	(86.5-115.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	56	53.7	104.3	(78.7-135.4)
Male	54	40.1	134.7	(101.2-175.8)	Female	62	62.3	99.5	(76.3-127.6)
Female	11	11.8	93.1	(46.4-166.6)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	495	503.8	98.3	(89.8-107.3)
Male	16	14.9	107.4	(61.3-174.4)	<b><u>Stomach</u></b>				
Female	19	13.5	140.5	(84.6-219.5)	Male	36	36.1	99.8	(69.9-138.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	24	24.5	97.8	(62.7-145.6)
Male	85	85.0	100.0	(79.8-123.6)	<b><u>Testis</u></b>				
Female	61	53.6	113.8	(87.0-146.1)	Male	21	29.2	72.0	(44.5-110.0)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	22	23.2	94.9	(59.4-143.7)	Male	41	41.9	97.7	(70.1-132.6)
Female	9	7.9	113.9	(52.0-216.2)	Female	119	136.3	87.3	(72.3-104.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	70	65.0	107.6	(83.9-136.0)	Female	156	148.2	105.3	(89.4-123.2)
Female	54	53.0	101.9	(76.6-133.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	2085	2029.7	102.7	(98.4-107.2)
Male	86	53.2	161.5	(129.2-199.5)	Female	2222	2311.3	96.1	(92.2-100.2)
Female	21	19.3	109.1	(67.5-166.8)					
<b><u>Lung and Bronchus</u></b>									
Male	330	266.6	123.8	(110.8-137.9)					
Female	354	317.2	111.6	(100.3-123.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	4	6.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	3	6.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.7	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	24	23.1	103.7	(66.4-154.3)
Male	1	0.7	nc	(nc-nc)	Female	18	20.9	86.1	(51.0-136.1)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	3.2	190.2	(69.4-413.9)					
Female	0	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wrentham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.9	100.9	(48.3-185.5)	Male	6	7.0	85.7	(31.3-186.6)
Female	2	4.1	nc	(nc-nc)	Female	11	6.1	179.0	(89.2-320.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.4	141.6	(64.6-268.8)
Female	59	49.4	119.5	(90.9-154.1)	Female	4	6.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	12.1	181.9	(113.9-275.4)	Female	3	4.3	nc	(nc-nc)
Female	11	13.2	83.2	(41.5-148.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	6	2.9	208.7	(76.2-454.2)	Male	4	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	45	37.3	120.6	(88.0-161.4)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	4	6.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	3	4.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	5	9.0	55.7	(18.0-130.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	4.2	nc	(nc-nc)	Female	6	11.1	54.2	(19.8-117.9)
Female	2	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	17	17.9	94.7	(55.1-151.7)	Male	158	143.2	110.3	(93.8-128.9)
Female	15	21.7	69.2	(38.7-114.2)	Female	149	162.1	91.9	(77.8-107.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Yarmouth

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	49.4	99.1	(73.3-131.1)	Male	41	27.3	150.2	(107.7-203.7)
Female	25	17.7	140.9	(91.1-208.0)	Female	50	19.4	257.9	(191.4-340.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.6	75.8	(24.4-176.9)	Male	8	9.0	89.3	(38.4-175.9)
Female	9	5.8	154.0	(70.3-292.3)	Female	7	7.6	92.6	(37.1-190.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	23	24.3	94.8	(60.1-142.2)
Female	178	154.6	115.1	(98.8-133.3)	Female	23	22.3	103.1	(65.4-154.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.2	nc	(nc-nc)	Male	21	16.6	126.4	(78.2-193.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	42	47.6	88.3	(63.6-119.4)	Female	11	14.1	77.9	(38.8-139.4)
Female	45	51.1	88.1	(64.3-117.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	18	16.0	112.4	(66.6-177.7)
Male	19	11.2	168.9	(101.7-263.8)	Female	14	17.8	78.6	(42.9-131.9)
Female	6	3.3	181.2	(66.2-394.4)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	147	127.9	114.9	(97.1-135.1)
Male	4	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	8	10.7	74.9	(32.2-147.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	7	6.7	105.0	(42.1-216.4)
Male	14	20.5	68.2	(37.2-114.4)	<b><u>Testis</u></b>				
Female	10	13.3	75.1	(35.9-138.1)	Male	3	2.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	6.2	nc	(nc-nc)	Male	11	7.5	146.7	(73.1-262.4)
Female	1	2.0	nc	(nc-nc)	Female	11	21.4	51.3	(25.6-91.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	31	17.1	181.0	(123.0-256.9)	Female	32	34.8	92.0	(62.9-129.9)
Female	18	12.7	142.1	(84.2-224.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	592	548.8	107.9	(99.4-116.9)
Male	18	13.4	134.7	(79.8-212.9)	Female	610	565.4	107.9	(99.5-116.8)
Female	8	5.1	156.8	(67.5-308.9)					
<b><u>Lung and Bronchus</u></b>									
Male	86	82.6	104.1	(83.3-128.6)					
Female	93	90.5	102.8	(82.9-125.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;